Cabergoline prevents ovarian hyperstimulation syndrome in high risk patients by disrupting
follicular fluid hormone microenvironmentally altering the follicular fluid levels of insulin
like growth hormone -I (IGF-I), antimullerian hormone (AMH), inhibin B and hepatocyte growth
factor (HGF) levels in women with PCOS and high risk of ovarian hyperstimulation syndrome
(OHSS).
Phase:
N/A
Details
Lead Sponsor:
Etlik Zubeyde Hanim Womens' Health and Teaching Hospital Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital